Mostrando 4 resultados de: 4
Filtros aplicados
Área temáticas
Problemas sociales y servicios a grupos(4)
Farmacología y terapéutica(3)
Medicina y salud(2)
Producción(2)
Enfermedades(1)
Origen
scopus(4)
EMA and FDA decisions based on flawed evidence to approve new cancer drugs negatively affect Latin American patients
OtherAbstract:Palabras claves:Autores:Cañás M., Carlos E. Durán, Chistiaens T.Fuentes:scopusSharp rise in the expenditures of targeted drugs in Ecuador: five-year (2010–2014) consumption of oncologic drugs in public and private hospitals
ArticleAbstract: Objective: In Ecuador, a new constitutional mandate (2008) allowed the government to implement freePalabras claves:Cáncer, drug utilization, ECUADOR, health expenditures, Latin America, molecular targeted therapy, oncologic drugsAutores:Carlos E. Durán, Christiaens T., Elseviers M., Rottey S., Vander Stichele R.Fuentes:scopusPolicies influencing access to new targeted oncologic drugs in Ecuadorian hospitals: an interrupted time series analysis
ArticleAbstract: Objective and methods: An interrupted time series analysis was performed to measure the impact of twPalabras claves:antineoplastic drugs, drug and therapeutic committees, drug policies, ECUADOR, interrupted time series analysis, molecular targeted therapyAutores:Carlos E. Durán, Christiaens T., Elseviers M., Patricia Granja, Rottey S., Vander Stichele R.Fuentes:scopusPotential negative impact of reputed regulators decisions on the approval status of new cancer drugs in Latin American countries: A descriptive analysis
ArticleAbstract: Background Many new cancer drugs are being approved by reputed regulatory authorities without evidenPalabras claves:Autores:Cañás M., Carlos E. Durán, Christiaens T., Elseviers M., Stichele R.V., Urtasun M.A.Fuentes:scopus